|
Persistent Identifier
|
perma:LIST.5HBVBO |
|
Publication Date
|
2025-09-26 |
|
Title
| PHOENIX-OITB – Developing and upgrading innovative nanopharmaceuticals from bench to clinics [* Cross-Reference *] |
|
Other Identifier
| DataCite: https://doi.org/10.5281/zenodo.16977381 |
|
Author
| Resch, Susanne (BioNanoNet Forschungsgesellschaft mbH) - ORCID: 0000-0003-1016-5979
Scheper, Johanna K. (BioNanoNet Forschungsgesellschaft mbH) - ORCID: 0000-0003-2410-2936
Cordoba, Alba (Nanomol Technologies) - ORCID: 0000-0002-2726-5119
Font, Albert (Leanbio S.L.)
Ventosa, Nora (ICMAB-CSIC, Centro de Investigación Biomédica en Red) - ORCID: 0000-0002-8008-4974
de la Fuente, Jesus M (Consejo Superior de Investigaciones Científicas) - ORCID: 0000-0003-1081-8482
Vinkovic Vrcek, Ivana (University of Rijeka, Institute for Medical Research and Occupational Health) - ORCID: 0000-0003-1382-5581
Srinivas, Mangala (Wageningen University & Research, Cenya Imaging BV) - ORCID: 0000-0002-3835-1995
Mohsenzada, Sulaiman (Research Center Pharmaceutical Engineering (Austria))
Schröter, Christian (Topas GmbH (Germany))
Holzer, Robert (Research Center for Non Destructive Testing (Austria))
Serchi, Tommaso (Luxembourg Institute of Science and Technology) - ORCID: 0000-0003-2386-3514
Günday-Türeli, Nazende (MyBiotech GmbH) - ORCID: 0000-0002-6310-4785 |
|
Point of Contact
|
Use email button above to contact.
LIST QDKM (LIST) |
|
Description
| The PHOENIX Open Innovation Test Bed (PHOENIX-OITB) is focused on overcoming the challenges of production of novel and innovative nano-pharmaceuticals (NPs) from lab scale to GMP quality and production, maximising bioavailability, stability and manufacturing to allow their implementation in the medicine field. PHOENIX-OITB is a non-profit, open and self-sustaining legal entity that works as a Single Entry Point (SEP) providing its end-users transparent processes and procedures as well as easy access to services and expertise needed to bridge the gapbetween the bench and the bedside, i.e., providing them with high-quality services, capable of Quality-Efficacy and Safety (QES) evaluation and production of nano-pharmaceuticals at large scales, meeting the regulatory and GMP requirements. (2025-08-28)
***This entry has been automatically imported via Datacite by LIST harvest scripts. Please refer to https://doi.org/10.5281/zenodo.16977381 for the original and latest version of the dataset and data downloads*** (2025-09-02) |
|
Subject
| Earth and Environmental Sciences; Medicine, Health and Life Sciences |
|
Keyword
| Nanomedicine (MeSH) |
|
Related Publication
| References: (HasVersion) 10.5281/zenodo.16977382 https://doi.org/10.5281/zenodo.16977382 |
|
Funding Information
| European Commission: 953110 ("Pharmaceutical Open Innovation Test Bed for Enabling Nano-pharmaceutical Innovative Products") |
|
Deposit Date
| 2025-08-28 |
|
Data Type
| Text |